Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach

Yuzhen Jin; Jun Chen; Cenfeng Liu; Wen‐Hao Wang; Yue Zhou; Kaiqing Zhang; Xiaolu Xiao; Gui-Xiang Chen; Xuejuan Zhang; Zhengwei Huang; Chuanbin Wu; Ying Huang

doi:10.1016/j.jare.2025.11.007

November 1, 2025Journal of Advanced ResearchOpen Access

Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to explore the efficacy of microparticles in treating pulmonary infections.
Development of tobramycin sponge-like microparticles.
Assessment of lectin affinity and respiratory variability tolerance.
Evaluation of treatment efficacy in pulmonary infection models.
Microparticles showed high affinity for lectins.
Demonstrated significant effectiveness against Pseudomonas aeruginosa infections.
Indicated improved treatment options for pulmonary conditions.

Implication

Microparticles reduce infections in pulmonary models, indicating potential for enhanced treatment options.

Abstract

This tobramycin spongy-like dry powder, identified as high lectin affinity and excellent respiratory variability tolerance, holds significant promise for the treatment of pulmonary infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jin et al. (2025) studied this question.

synapsesocial.com/papers/6925435ec0ce034ddc35808e https://doi.org/10.1016/j.jare.2025.11.007

View Full Paper

Ask AI

Bookmark

Share

Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach

Key Points

Implication

Abstract

Discussion

Cite This Study

Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading